For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Trump’s State of the Union: A closer look at the claims
Last night, President Trump delivered a State of the Union address filled with optimism, applause lines, and bold claims about the country’s direction. There…
Citation
‘Just the beginning of enormous growth’: White House heralds strong jobs report
The Black Chronicle cited CEI’s expert on job growth in healthcare Senior Economist with the Competitive Enterprise Institute Ryan Young also interpreted the siloed…
Blog
FDA’s Moderna decision demonstrates how science and government are incompatible
Last week, the FDA announced that it would not be considering Moderna’s application for a new flu vaccine because the control group Moderna used…
Search Posts
City Journal
Cuomo’s Vaccine Overreach
The New York governor’s incorrect claim that his state can review FDA vaccine approval will lead to more contagion and illness. New York governor Andrew…
Inside Sources
The Double Standard for Nicotine and Cannabis
The U.S. House of Representatives may soon vote on a historic measure to end federal prohibition on cannabis. Ironically, just as the public and political…
Study
The Double Standards of Cannabis and Nicotine
View Full Document as PDF Executive Summary The principal benefit of recreational cannabis, as the name implies, is recreation. Many who enjoy using…
National Review
Cancel Culture Comes to Medicine
Cancel culture has come to medicine. Dr. Scott Atlas, who was chairman of neuroradiology at Stanford’s medical school until 2012 and more recently a senior fellow…
News Release
Report: Politics, Not Science, Drives Double Standard on Cannabis, Nicotine Policies
As the House votes on a bill this month to end the federal prohibition on cannabis – once unthinkable – a new Competitive Enterprise…
Blog
Trump’s Drug Price Controls are a Lousy Deal for Patients
Prescription drug prices are popular targets for lawmakers—especially in an election year. Still, it came as quite a surprise when President Trump issued an…